Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

(2017) Ahmet Zehir et al.   NATURE MEDICINE

Insulin growth factor 1 like receptor (IGF-1R)

(2016) Gopal Iyer et al.   BMC CANCER

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial

(2016) J. Randolph Hecht et al.   JOURNAL OF CLINICAL ONCOLOGY

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

(2016) Arlene Chan et al.   LANCET ONCOLOGY

Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity

(2016) Wen Fong Ooi et al.   Nature Communications

The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes

(2016) Bernard Pereira et al.   Nature Communications

Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome

(2015) Karen Gambaro et al.   BMC CANCER

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboringHER2oncogene alterations

(2015) Ken Suzawa et al.   CANCER SCIENCE

IGF-1R expression is associated with HPV-negative status and adverse survival in head and neck squamous cell cancer

(2015) O. T. Dale et al.   CARCINOGENESIS

Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas

(2015) S. M. Leto et al.   CLINICAL CANCER RESEARCH

Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)

(2015) Donavan T. Cheng et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study

(2014) Taroh Satoh et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive molecular characterization of gastric adenocarcinoma

(2014) Adam J. Bass et al.   NATURE

MutationTaster2: mutation prediction for the deep-sequencing age

(2014) Jana Marie Schwarz et al.   NATURE METHODS

Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing

(2014) Swee Seong Wong et al.   Nature Communications

Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell-like Properties in Cancer Cells

(2013) K. Shien et al.   CANCER RESEARCH

Novel Germline Mutation in the Transmembrane Domain of HER2 in Familial Lung Adenocarcinomas

(2013) Hiromasa Yamamoto et al.   JNCI-Journal of the National Cancer Institute

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

Knockdown of the Epidermal Growth Factor Receptor Gene to Investigate Its Therapeutic Potential for the Treatment of Non–Small-Cell Lung Cancers

(2012) Kazuhiko Shien et al.   Clinical Lung Cancer

Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy

(2012) Kazuhiko Shien et al.   LUNG CANCER

IGFBP7 Binds to the IGF-1 Receptor and Blocks Its Activation by Insulin-Like Growth Factors

(2012) V. Evdokimova et al.   Science Signaling

Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

(2012) Ron Bose et al.   Cancer Discovery

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

IGFBP7 downregulation is associated with tumor progression and clinical outcome in hepatocellular carcinoma

(2011) Yoshito Tomimaru et al.   INTERNATIONAL JOURNAL OF CANCER

Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers

(2011) Kenji Tomizawa et al.   LUNG CANCER

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells

(2009) Junichi Soh et al.   PLoS One

Co-Targeting Insulin-Like Growth Factor I Receptor and HER2: Dramatic Effects of HER2 Inhibitors on Nonoverexpressing Breast Cancer

(2008) A. K. Chakraborty et al.   CANCER RESEARCH

PIK3CA Mutations and Copy Number Gains in Human Lung Cancers

(2008) H. Yamamoto et al.   CANCER RESEARCH

METgene amplification orEGFRmutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors

(2008) Takafumi Kubo et al.   INTERNATIONAL JOURNAL OF CANCER